InflaRx (IFRX) Other Operating Expenses (2016 - 2026)
InflaRx (IFRX) posted Other Operating Expenses of -$126524.8 for Q1 2026, up 90.75% sequentially from -$1.4 million in Q3 2025, and up 91.75% YoY from -$65984.3 in Q1 2025.
InflaRx (IFRX) Other Operating Expenses (2016 - 2026) Analysis & Trends
InflaRx has reported Other Operating Expenses for 11 years, with the latest figure at -$126524.8 in Q1 2026.
- Quarterly Other Operating Expenses rose 91.75% year-over-year to -$126524.8 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.5 million (up 56.18% YoY) and the FY2022 annual result came in at -$55223.0 billion, down 21808543.69% from the prior year.
- Other Operating Expenses improved to -$126524.8 in Q1 2026 per IFRX's latest filing, from -$1.4 million in the prior quarter.
- Over five years, Other Operating Expenses peaked at $19685.6 billion in Q1 2023 and troughed at -$53456.5 billion in Q4 2022.
- A 5-year average of -$4448.3 billion and a median of -$1.6 million in 2023 frame the typical range for Other Operating Expenses.
- The sharpest annual moves came in 2022 and 2023: Other Operating Expenses tumbled 5.7512495248749355e+23% in 2022, then soared 100.0% in 2023.
- Over 5 years, Other Operating Expenses stood at -$53456.5 billion in 2022, then surged by 100.0% to -$1.7 million in 2023, then fell by 10.26% to -$1.9 million in 2024, then climbed by 27.1% to -$1.4 million in 2025, then soared by 90.75% to -$126524.8 in 2026.
- According to Business Quant data, Other Operating Expenses over the past three periods registered -$126524.8, -$1.4 million, and -$1.5 million for Q1 2026, Q3 2025, and Q1 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -126,524.82 |
| Sep 30, 2025 | -1.37 Mn |
| Mar 31, 2025 | -1.53 Mn |
| Sep 30, 2024 | -1.88 Mn |
| Mar 31, 2024 | -1.59 Mn |
| Sep 30, 2023 | -1.70 Mn |
| Mar 31, 2023 | 19,685.57 Bn |
| Dec 31, 2022 | -53,456.47 Bn |
| Sep 30, 2022 | -10,712.54 Bn |
| Jun 30, 2022 | -23.86 Mn |
| Sep 30, 2021 | 0.00 |
| Jun 30, 2021 | -27.21 Mn |
| Mar 31, 2021 | -1.21 |
| Mar 31, 2020 | 1.10 |
| Dec 31, 2019 | 0.01 |
| Jun 30, 2019 | 0.00 |
| Dec 31, 2018 | 1.14 Mn |
| Sep 30, 2018 | 68,624.62 |
| Jun 30, 2018 | 52,511.55 |
| Mar 31, 2018 | 85,997.30 |